20多年來，羅氏致力于為血液病患者開發藥物，在這一治療領域積累了豐富的經驗與知識。現如今，羅氏的投入遠超以往，努力為各類血液病患者提供創新的治療選擇。目前公司獲批的藥物包括美羅華^{®<\/sup>（利妥昔單抗）、佳羅華^{®<\/sup>（奧妥珠單抗）、優羅華^{®<\/sup>（維泊妥珠單抗）、高羅華^{®<\/sup>（格菲妥單抗）和舒友立樂^{®<\/sup>（艾美賽珠單抗）；另外還包括淋巴瘤創新藥 Mosunetuzumab（CD20xCD3 T細胞-雙特異性抗體）和Crovalimab（可伐利單抗）。羅氏的科學專業知識，加上廣泛的產品組合和產品線，也為開發進一步改善患者生活的聯合治療方案提供了獨特的機會。<\/p> \n}}}}}

羅氏是一家全球領先的生物技術企業，總部在瑞士，擁有125余年悠久歷史。結合制藥和診斷兩大領域的獨特優勢，我們致力于通過個體化醫療推動科學進步，改善人類生活。作為全球制藥和診斷領域的領導者，羅氏在抗腫瘤、免疫、抗感染、眼科和神經科學系統領域擁有一流的差異化藥物。創新是羅氏的DNA。作為一家以創新為驅動的制藥公司，每年，羅氏集團在研發創新領域投入巨大。2021年，羅氏全球的研發投入達到150億美元，約占公司收入的20%。<\/p> \n

\n \n \n \n \n \n \n \n
<optgroup id="kgssg"></optgroup>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区
^{[1] <\/sup>Roche. FDA approves Roche’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma. 2023. https:\/\/www.roche.com\/media\/releases\/med-cor-2023-06-16<\/a><\/span><\/p> <\/td> \n <\/tr> \n}
^{[2] <\/sup>Coiffier B, et al. Blood. 2010;116(12):2040-2045.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[3] <\/sup>Varma G, Goldstein J, Advani RH. Novel agents in relapsed\/refractory diffuse large B-cell lymphoma. Hematol Oncol. 2023;41 Suppl 1:92-106.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[4] <\/sup>Hutchings M, et al. Glofitamab monotherapy in patients with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL):extended follow-up and landmark analyses from a pivotal phase II study. 2023 ASCO Poster 7550; 2023 EHA. Poster 1129; 2023 ICML Oral 95.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[5] <\/sup>Song YQ, et al. Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2023 Oct 19. doi: 10.3324\/haematol.2023.283802. Epub ahead of print.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n}
<\/p>"]; $("#dvExtra").html(content_array[0]);})();
<center id="kgssg"></center>